JY
AMRX icon

Jeff Yass’s Amneal Pharmaceuticals AMRX Stock Holding History

Jeff Yass’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$126K – 13104
2025
Q4 		$126K Buy
+10,000
New +$114K ﹤0.01% 11313
2025
Q3 		– Sell
-37,400
Closed -$303K – 12294
2025
Q2 		$303K Sell
37,400
-13,000
-26% -$98K ﹤0.01% 10311
2025
Q1 		$422K Sell
50,400
-22,000
-30% -$184K ﹤0.01% 9282
2024
Q4 		$573K Buy
72,400
+25,600
+55% +$215K ﹤0.01% 8330
2024
Q3 		$389K Buy
46,800
+3,600
+8% +$28.2K ﹤0.01% 9049
2024
Q2 		$274K Sell
43,200
-22,300
-34% -$142K ﹤0.01% 9651
2024
Q1 		$397K Buy
+65,500
New +$369K ﹤0.01% 9054
2023
Q3 		– Sell
-33,100
Closed -$103K – 11950
2023
Q2 		$103K Buy
33,100
+18,800
+131% +$40K ﹤0.01% 10930
2023
Q1 		$19.9K Sell
14,300
-7,100
-33% -$14.1K ﹤0.01% 12054
2022
Q4 		$42.6K Sell
21,400
-64,900
-75% -$145K ﹤0.01% 11476
2022
Q3 		$174K Sell
86,300
-18,400
-18% -$51.6K ﹤0.01% 11037
2022
Q2 		$333K Sell
104,700
-147,900
-59% -$536K ﹤0.01% 9289
2022
Q1 		$1.05M Buy
252,600
+75,800
+43% +$336K ﹤0.01% 6978
2021
Q4 		$847K Sell
176,800
-210,700
-54% -$1.05M ﹤0.01% 7736
2021
Q3 		$2.07M Buy
387,500
+121,300
+46% +$611K ﹤0.01% 5756
2021
Q2 		$1.36M Buy
266,200
+20,200
+8% +$115K ﹤0.01% 6907
2021
Q1 		$1.66M Buy
246,000
+52,400
+27% +$290K ﹤0.01% 6381
2020
Q4 		$885K Buy
193,600
+94,400
+95% +$418K ﹤0.01% 6996
2020
Q3 		$385K Sell
99,200
-16,400
-14% -$70.1K ﹤0.01% 8212
2020
Q2 		$550K Buy
115,600
+14,900
+15% +$61.4K ﹤0.01% 7169
2020
Q1 		$350K Buy
100,700
+35,800
+55% +$152K ﹤0.01% 7680
2019
Q4 		$313K Sell
64,900
-99,000
-60% -$344K ﹤0.01% 7932
2019
Q3 		$475K Buy
163,900
+110,500
+207% +$386K ﹤0.01% 7414
2019
Q2 		$383K Buy
+53,400
New +$546K ﹤0.01% 7821
2018
Q3 		– Sell
-19,600
Closed -$322K – 9139
2018
Q2 		$322K Buy
+19,600
New +$344K ﹤0.01% 7689

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Jeff Yass's AMRX Position: Q2 2026 in Review

Jeff Yass reduced its Amneal Pharmaceuticals (AMRX) stake by 59% in Q2 2026, selling an estimated $422K and leaving 21,774 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #10554.

Jeff Yass first reported a position in AMRX in Q2 2018 and has held it in 30 quarters since. The position peaked at $16.7M in Q4 2025. 305 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Jeff Yass held 21,774 shares of Amneal Pharmaceuticals worth $377K as of Q2 2026.
  • Jeff Yass sold 30,769 Amneal Pharmaceuticals shares in Q2 2026, an estimated $422K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10554 holding.
  • Jeff Yass first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
  • Jeff Yass's Amneal Pharmaceuticals position peaked at $16.7M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.